Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ZeaChem was an industrial biotechnology company focused on the development of biorefineries for the production of advanced biofuels and bio-based chemicals. The company utilized a proprietary hybrid technology that combined acetogen fermentation with chemical catalysis to convert cellulosic biomass into high-value products such as ethanol, acetic acid, and ethyl acetate. By employing the bacterium Moorella thermoacetica, ZeaChem achieved high carbon efficiency, significantly reducing greenhouse gas emissions compared to traditional petroleum-based processes. Their process was unique in that it avoided the production of carbon dioxide during the fermentation stage, maximizing the yield of carbon from feedstock to product. Although the company successfully operated a demonstration-scale plant in Boardman, Oregon, it faced challenges in reaching full commercial scale and has since ceased major operations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ZeaChem.